BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen
LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024.
"We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to higher interest rates, I believe our performance shows that we are well-positioned for greater gains once our market returns to normal and dental practitioners have the purchasing power they have historically been accustomed to in the past. The positive response to the U.S. launch of our Waterlase iPlus Premier laser system last quarter underscores the strong interest in our industry-leading products and our commitment to innovation and customer satisfaction."
Second Quarter Financial Results
Net revenue for the quarter ended June 30, 2024, was $11.6 million compared to net revenue of $14.3 million for the quarter ended June 30, 2023. U.S. laser revenue was $3.6 million for the quarter ended June 30, 2024, compared to U.S. laser revenue of $6.3 million for the quarter ended June 30, 2023. U.S. consumables and other revenue for the quarter ended June 30, 2024, which consists of revenue from consumable products such as disposable tips, decreased 5% year over year. International laser revenue was $2.4 million for the quarter ended June 30, 2024, compared to $2.5 million for the quarter ended June 30, 2023. International consumables and other revenue for the quarter ended June 30, 2024, which consists of revenue from consumable products such as disposable tips, decreased 12% year over year.
Gross margin for the quarter ended June 30, 2024, was 40% compared to 43% for the quarter ended June 30, 2023. Total operating expenses were $7.8 million for the quarter ended June 30, 2024, compared to $10.0 million for the quarter ended June 30, 2023, a 22% decrease year over year. Operating loss for the quarter ended June 30, 2024, was $3.2 million, compared to an operating loss of $3.9 million for the quarter ended June 30, 2023, an improvement of 17% year over year.
The Company had cash and cash equivalents of approximately $5.3 million on June 30, 2024.
Net Loss and Adjusted EBITDA
The reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's Adjusted EBITDA and Adjusted EBITDA per share.
Net loss attributable to common stockholders for the quarter ended June 30, 2024, was $2.8 million, or $0.08 per share, compared to a net loss of $14.2 million, or $26.14 per share, for the quarter ended June 30, 2023. Adjusted EBITDA for the quarter ended June 30, 2024, was a loss of $2.5 million, or $0.08 per share, compared with an Adjusted EBITDA loss of $2.3 million, or $4.24 per share, for the quarter ended June 30, 2023.
Full Year 2024 Financial Guidance
Based on six months of operating and financial results, current market uncertainty, as well as the outlook for the remainder of the year the Company is updating full-year 2024 financial guidance. The Company now expects 2024 full year revenue to be similar to that achieved in 2023, reflecting the headwinds the Company experienced in the first half of 2024 and a somewhat lower capital equipment revenue forecast for the last half of 2024.
The Company is also updating its Adjusted EBITDA expectations for the full year of 2024 based on the performance in the first half of 2024 to a loss of between $6 million and $8 million, an improvement over the full-year 2023 Adjusted EBITDA loss of $12.8 million (Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, severance expense, stock-based and other non-cash compensation, stock warrant issuance costs, gain or losses on warrants, and the change in inventory reserves and allowance for doubtful accounts).
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. As of December 31, 2023, BIOLASE's proprietary laser products incorporate approximately 241 active patents and 21 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2023, BIOLASE has sold over 47,700 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's expected revenue and revenue growth. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release and includes statements regarding being well-positioned for greater gains once our market returns to normal and dental practitioners have the purchasing power they have historically been accustomed to in the past, the strong interest in our industry-leading products and our commitment to innovation and customer satisfaction, the expectation that 2024 full year revenue to be similar to that achieved in 2023, reflecting the headwinds the Company experienced in the first half of 2024 and a somewhat lower capital equipment revenue forecast for the last half of 2024 and and expected Adjusted EBITDA results for the full year of 2024. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the ability to sustain growth, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, and ability to increase revenue, risks associated with managing the growth of the business, substantial doubt regarding BIOLASE's ability to continue as a going concern, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com
tkehrli@evcgroup.com
BIOLASE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited, in thousands, except per share data)
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| June 30, |
|
| June 30, |
| ||||||||||
|
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| ||||
| Net revenue |
| $ | 11,555 |
|
| $ | 14,286 |
|
| $ | 21,687 |
|
| $ | 24,753 |
|
| Cost of revenue |
|
| 6,946 |
|
|
| 8,168 |
|
|
| 13,741 |
|
|
| 15,299 |
|
| Gross profit |
|
| 4,609 |
|
|
| 6,118 |
|
|
| 7,946 |
|
|
| 9,454 |
|
| Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sales and marketing |
|
| 3,694 |
|
|
| 6,189 |
|
|
| 7,077 |
|
|
| 10,812 |
|
| General and administrative |
|
| 3,064 |
|
|
| 2,357 |
|
|
| 6,260 |
|
|
| 4,815 |
|
| Engineering and development |
|
| 1,071 |
|
|
| 1,444 |
|
|
| 2,354 |
|
|
| 2,991 |
|
| Total operating expenses |
|
| 7,829 |
|
|
| 9,990 |
|
|
| 15,691 |
|
|
| 18,618 |
|
| Loss from operations |
|
| (3,220 | ) |
|
| (3,872 | ) |
|
| (7,745 | ) |
|
| (9,164 | ) |
| Loss on foreign currency transactions |
|
| (112 | ) |
|
| (235 | ) |
|
| (208 | ) |
|
| (215 | ) |
| Interest expense, net |
|
| (586 | ) |
|
| (583 | ) |
|
| (1,208 | ) |
|
| (1,160 | ) |
| Other income (loss), net |
|
| 1,140 |
|
|
| (147 | ) |
|
| (82 | ) |
|
| (147 | ) |
| Non-operating income (loss), net |
|
| 442 |
|
|
| (965 | ) |
|
| (1,498 | ) |
|
| (1,522 | ) |
| Loss before income tax provision |
|
| (2,778 | ) |
|
| (4,837 | ) |
|
| (9,243 | ) |
|
| (10,686 | ) |
| Income tax provision |
|
| (20 | ) |
|
| (31 | ) |
|
| (40 | ) |
|
| (31 | ) |
| Net loss |
|
| (2,798 | ) |
|
| (4,868 | ) |
|
| (9,283 | ) |
|
| (10,717 | ) |
| Other comprehensive loss items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Foreign currency translation adjustments |
|
| (20 | ) |
|
| 39 |
|
|
| (106 | ) |
|
| 119 |
|
| Comprehensive loss |
| $ | (2,818 | ) |
| $ | (4,829 | ) |
| $ | (9,389 | ) |
| $ | (10,598 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Net loss |
| $ | (2,798 | ) |
| $ | (4,868 | ) |
| $ | (9,283 | ) |
| $ | (10,717 | ) |
| Deemed dividend on convertible preferred stock |
|
| - |
|
|
| (9,377 | ) |
|
| - |
|
|
| (9,377 | ) |
| Net loss attributable to common stockholders |
| $ | (2,798 | ) |
| $ | (14,245 | ) |
| $ | (9,283 | ) |
| $ | (20,094 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic and Diluted |
| $ | (0.08 | ) |
| $ | (26.14 | ) |
| $ | (0.36 | ) |
| $ | (45.98 | ) |
| Shares used in the calculation of net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic and Diluted |
|
| 33,391 |
|
|
| 545 |
|
|
| 25,616 |
|
|
| 437 |
|
BIOLASE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands, except per share data)
|
| June 30, |
|
| December 31, |
| ||
|
| 2024 |
|
| 2023 |
| ||
| ASSETS |
|
|
|
|
|
| ||
| Current assets: |
|
|
|
|
|
| ||
| Cash and cash equivalents |
| $ | 5,272 |
|
| $ | 6,566 |
|
| Accounts receivable, less allowance of $329 and $244 as of June 30, 2024 and December 31, 2023, respectively |
|
| 4,842 |
|
|
| 5,483 |
|
| Inventory |
|
| 10,904 |
|
|
| 11,433 |
|
| Prepaid expenses and other current assets |
|
| 1,076 |
|
|
| 1,381 |
|
| Total current assets |
|
| 22,094 |
|
|
| 24,863 |
|
| Property, plant, and equipment, net |
|
| 4,263 |
|
|
| 5,525 |
|
| Goodwill |
|
| 2,926 |
|
|
| 2,926 |
|
| Right-of-use assets, leases |
|
| 1,101 |
|
|
| 1,519 |
|
| Other assets |
|
| 257 |
|
|
| 268 |
|
| Total assets |
| $ | 30,641 |
|
| $ | 35,101 |
|
| LIABILITIES, CONVERTIBLE REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) |
|
|
|
|
|
|
|
|
| Current liabilities: |
|
|
|
|
|
|
|
|
| Accounts payable |
| $ | 5,491 |
|
| $ | 6,065 |
|
| Accrued liabilities |
|
| 7,662 |
|
|
| 7,518 |
|
| Stock warrant liability |
|
| 2,616 |
|
|
| 1,363 |
|
| Deferred revenue, current portion |
|
| 2,132 |
|
|
| 2,452 |
|
| Current portion of term loans, net of discount |
|
| 13,275 |
|
|
| 2,265 |
|
| Total current liabilities |
|
| 31,176 |
|
|
| 19,663 |
|
| Deferred revenue |
|
| 186 |
|
|
| 256 |
|
| Warranty accrual |
|
| 843 |
|
|
| 593 |
|
| Non-current term loans |
|
| 150 |
|
|
| 11,782 |
|
| Non-current operating lease liability |
|
| 315 |
|
|
| 772 |
|
| Other liabilities |
|
| 97 |
|
|
| 79 |
|
| Total liabilities |
|
| 32,767 |
|
|
| 33,145 |
|
| Mezzanine Equity: |
|
|
|
|
|
|
|
|
| Series H Convertible Redeemable Preferred stock, par value $0.001 per share |
|
| 346 |
|
|
| 346 |
|
| Series J Convertible Redeemable Preferred stock, par value $0.001 per share |
|
| 1,857 |
|
|
| 1,857 |
|
| Total mezzanine equity |
|
| 2,203 |
|
|
| 2,203 |
|
| Stockholders' equity (deficit): |
|
|
|
|
|
|
|
|
| Common stock, par value $0.001 per share |
|
| 33 |
|
|
| 3 |
|
| Additional paid-in capital |
|
| 322,380 |
|
|
| 317,103 |
|
| Accumulated other comprehensive loss |
|
| (659 | ) |
|
| (553 | ) |
| Accumulated deficit |
|
| (326,083 | ) |
|
| (316,800 | ) |
| Total stockholders' equity (deficit) |
|
| (4,329 | ) |
|
| (247 | ) |
| Total liabilities, convertible redeemable preferred stock and stockholders' equity (deficit) |
| $ | 30,641 |
|
| $ | 35,101 |
|
BIOLASE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
|
| Six Months Ended |
| |||||
|
| June 30, |
| |||||
|
| 2024 |
|
| 2023 |
| ||
| Cash Flows from Operating Activities: |
|
|
|
|
|
| ||
| Net loss |
| $ | (9,283 | ) |
| $ | (10,717 | ) |
| Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: |
|
|
|
|
|
|
|
|
| Depreciation |
|
| 1,310 |
|
|
| 1,573 |
|
| Provision for bad debts |
|
| 86 |
|
|
| 42 |
|
| Provision for inventory excess and obsolescence |
|
| 76 |
|
|
| - |
|
| Amortization of debt issuance costs |
|
| 242 |
|
|
| 214 |
|
| Change in fair value of warrants |
|
| (514 | ) |
|
| (78 | ) |
| Issuance costs for common stock warrants |
|
| 830 |
|
|
| 224 |
|
| Stock-based compensation |
|
| 67 |
|
|
| 775 |
|
| Gain on disposal of fixed assets |
|
| (232 | ) |
|
| - |
|
| Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
| Accounts receivable |
|
| 555 |
|
|
| 82 |
|
| Inventory |
|
| 374 |
|
|
| (163 | ) |
| Prepaid expenses and other current assets |
|
| 734 |
|
|
| 713 |
|
| Accounts payable and accrued liabilities |
|
| (527 | ) |
|
| (1,903 | ) |
| Deferred revenue |
|
| (390 | ) |
|
| 18 |
|
| Net cash and cash equivalents used in operating activities |
|
| (6,672 | ) |
|
| (9,220 | ) |
| Cash Flows from Investing Activities: |
|
|
|
|
|
|
|
|
| Purchases of property, plant, and equipment |
|
| (27 | ) |
|
| (944 | ) |
| Proceeds from disposal of property, plant, and equipment |
|
| 284 |
|
|
| - |
|
| Net cash and cash equivalents provided by (used in) investing activities |
|
| 257 |
|
|
| (944 | ) |
| Cash Flows from Financing Activities: |
|
|
|
|
|
|
|
|
| Proceeds from the sale of common stock and pre-funded warrants, net of fees |
|
| 2,786 |
|
|
| 8,502 |
|
| Proceeds from the sale of Series H Convertible Preferred Stock, net of fees |
|
| - |
|
|
| 2,738 |
|
| Proceeds from the sale of warrants, net of fees |
|
| 3,020 |
|
|
| 918 |
|
| Principal payment on loan |
|
| (865 | ) |
|
| - |
|
| Proceeds from the exercise of common stock warrants |
|
| 8 |
|
|
| 115 |
|
| Proceeds from the exercise of preferred share warrants |
|
| 270 |
|
|
| 520 |
|
| Net cash and cash equivalents provided by financing activities |
|
| 5,219 |
|
|
| 12,793 |
|
| Effect of exchange rate changes |
|
| (98 | ) |
|
| 120 |
|
| (Decrease) increase in cash and cash equivalents |
|
| (1,294 | ) |
|
| 2,749 |
|
| Cash and cash equivalents, beginning of period |
|
| 6,566 |
|
|
| 4,181 |
|
| Cash and cash equivalents, end of period |
| $ | 5,272 |
|
| $ | 6,930 |
|
| Supplemental cash flow disclosure: |
|
|
|
|
|
|
|
|
| Cash paid for interest |
| $ | 968 |
|
| $ | 930 |
|
| Cash received for interest |
| $ | 3 |
|
| $ | 5 |
|
| Cash paid for income taxes |
| $ | 42 |
|
| $ | 12 |
|
| Cash paid for operating leases |
| $ | 157 |
|
| $ | 159 |
|
| Non-cash property, plant and equipment additions acquired under inventory |
| $ | 78 |
|
| $ | - |
|
| Common stock issued upon cashless warrant exercise |
| $ | 1,989 |
|
| $ | - |
|
| Common stock issued upon exercise of preferred stock |
| $ | 528 |
|
| $ | 10,980 |
|
| Non-cash right-of-use assets obtained in exchange for lease obligation |
| $ | - |
|
| $ | 483 |
|
Non-GAAP Financial Measures
In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. ("GAAP"), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents.
Adjusted EBITDA is defined as net loss before interest, taxes, depreciation, stock-based and other non-cash compensation, severance expense, change in allowance for doubtful accounts, increase in inventory reserves, stock warrant issuance costs, and loss on warrants. Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.
BIOLASE, INC.
Reconciliation of GAAP Net Loss to Adjusted EBITDA and
GAAP Net Loss Per Share to Adjusted EBITDA Per Share
(Unaudited, in thousands, except per share data)
|
| Three Months Ended |
|
| Six Months Ended |
| ||||||||||
|
| June 30, |
|
| June 30, |
| ||||||||||
|
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| ||||
| GAAP net loss attributable to common stockholders |
| $ | (2,798 | ) |
| $ | (14,245 | ) |
| $ | (9,283 | ) |
| $ | (20,094 | ) |
| Deemed dividend on convertible preferred stock |
|
| - |
|
|
| 9,377 |
|
|
| - |
|
|
| 9,377 |
|
| GAAP net loss |
| $ | (2,798 | ) |
| $ | (4,868 | ) |
| $ | (9,283 | ) |
| $ | (10,717 | ) |
| Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest expense, net |
|
| 586 |
|
|
| 583 |
|
|
| 1,208 |
|
|
| 1,160 |
|
| Income tax provision |
|
| 20 |
|
|
| 31 |
|
|
| 40 |
|
|
| 31 |
|
| Depreciation |
|
| 650 |
|
|
| 1,424 |
|
|
| 1,310 |
|
|
| 1,573 |
|
| Severance expense |
|
| - |
|
|
| 229 |
|
|
| 182 |
|
|
| 229 |
|
| Change in allowance for doubtful accounts |
|
| 113 |
|
|
| 59 |
|
|
| 86 |
|
|
| 42 |
|
| Stock-based and other non-cash compensation |
|
| (46 | ) |
|
| 84 |
|
|
| 67 |
|
|
| 775 |
|
| Stock warrant issuance costs |
|
| - |
|
|
| 224 |
|
|
| 830 |
|
|
| 224 |
|
| Gain on warrants |
|
| (1,070 | ) |
|
| (77 | ) |
|
| (514 | ) |
|
| (77 | ) |
| Adjusted EBITDA |
| $ | (2,545 | ) |
| $ | (2,311 | ) |
| $ | (6,074 | ) |
| $ | (6,760 | ) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| GAAP net loss attributable to common stockholders per share, basic and diluted |
| $ | (0.08 | ) |
| $ | (26.14 | ) |
| $ | (0.36 | ) |
| $ | (45.98 | ) |
| Deemed dividend on convertible preferred stock |
|
| - |
|
|
| 17.21 |
|
|
| - |
|
|
| 21.46 |
|
| GAAP net loss per share, basic and diluted |
| $ | (0.08 | ) |
| $ | (8.93 | ) |
| $ | (0.36 | ) |
| $ | (24.52 | ) |
| Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest expense, net |
|
| 0.02 |
|
|
| 1.07 |
|
|
| 0.05 |
|
|
| 2.66 |
|
| Income tax provision |
|
| - |
|
|
| 0.06 |
|
|
| - |
|
|
| 0.07 |
|
| Depreciation |
|
| 0.02 |
|
|
| 2.61 |
|
|
| 0.05 |
|
|
| 3.59 |
|
| Severance expense |
|
| - |
|
|
| 0.42 |
|
|
| 0.01 |
|
|
| 0.52 |
|
| Change in allowance for doubtful accounts |
|
| - |
|
|
| 0.11 |
|
|
| - |
|
|
| 0.10 |
|
| Stock-based and other non-cash compensation |
|
| - |
|
|
| 0.15 |
|
|
| - |
|
|
| 1.77 |
|
| Stock warrant issuance costs |
|
| - |
|
|
| 0.41 |
|
|
| 0.03 |
|
|
| 0.51 |
|
| Gain on warrants |
|
| (0.04 | ) |
|
| (0.14 | ) |
|
| (0.02 | ) |
|
| (0.17 | ) |
| Adjusted EBITDA per share, basic and diluted |
| $ | (0.08 | ) |
| $ | (4.24 | ) |
| $ | (0.24 | ) |
| $ | (15.47 | ) |
Contact Information:
Todd Kehrli
IR
tkehrli@evcgroup.com
SOURCE: BIOLASE, Inc.
View the original press release on accesswire.com
Editor Details
-
Company:
- AccessWire
- Website:
